Galapagos has been granted a patent for compounds that inhibit ADAMTS, which can be used for the treatment of inflammatory conditions and diseases involving cartilage degradation. The patent also covers methods for producing these compounds and pharmaceutical compositions containing them. GlobalData’s report on Galapagos gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Galapagos, Peptide pharmacophores was a key innovation area identified from patents. Galapagos's grant share as of September 2023 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11718588B2) discloses a compound of formula (II) and its various derivatives. The compound can be substituted with different groups such as imidazolyl, pyrazolyl, oxazolyl, pyridinyl, pyrimidinyl, or pyrazinyl. These groups can further be optionally substituted with a C1 alkylC2-4 alkyl or C3 monocyclic cycloalkyl. The patent also claims a method of making the compound of formula (II) by reacting a compound of formula (I).
The patent further describes several methods of making different compounds, including compound (173), compound (203), compound (204), compound (205), compound (207), compound (357), compound (403), and compound (416). These methods involve various synthetic processes and reactions.
Additionally, the patent mentions that the compound of formula (II) can have different substituents on R1, such as ethyl, propyl, isopropyl, and tert-butyl. Specifically, it highlights that R1 can be ethyl.
Overall, this granted patent provides valuable information about a compound of formula (II) and its derivatives, along with methods of synthesizing these compounds. The disclosed compounds and methods may have potential applications in various fields, such as pharmaceuticals, agrochemicals, or materials science. Further research and development based on this patent could lead to the discovery of new compounds with desirable properties and potential commercial value.
To know more about GlobalData’s detailed insights on Galapagos, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.